Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

DPT Laboratories, Confab Announce Integration

By Pharmaceutical Processing | October 16, 2013

Pharmaceutical contract development and manufacturing organizations (CDMOs) DPT Laboratories, based in San Antonio, Texas, and Confab, based in Saint-Hubert, Quebec, today announced the integration of the organizations under the leadership of Paul Johnson, Group President and COO.
Both DPT and Confab are owned by Renaissance Acquisition Holdings, LLC, a portfolio company of RoundTable Healthcare Partners, and represent its CDMO holdings.
The integration includes a re-branding and new logo for Confab, identifying it as a DPT company.  A primary focus of the integration is for DPT’s established sales and marketing team to introduce Confab’s specialized expertise in complex solid, semi-solid and liquid dosage forms to new pharmaceutical industry clients, especially in the U.S. market.
The management teams for both companies will remain in place, with Confab development and manufacturing continuing to operate under the direction of President and General Manager Nathalie Brisson.        
“Confab is one of the most-respected pharmaceutical outsourcing organizations in Canada, with more than 30 years’ experience in manufacturing, packaging and analyzing a wide range of projects for both large and small pharmaceutical companies,” said Johnson. 
“The integration will provide our sales team with complimentary manufacturing capabilities and a broader range of services to offer to our customers,” he added.  “At the same time, the increased marketing support will leverage the continued investment Confab has made in infrastructure and capabilities, paying dividends in new client development and increased sales growth.” 
Confab has 350 employees and a 140,000-square-foot, cGMP-compliant turnkey facility, which is licensed by the Health Canada Therapeutic Products Directorate, as well as the United States FDA.          
“DPT’s sales and marketing team has a proven track record for building client relationships and driving growth,” said Brisson. “For our team at Confab, this will mean broader recognition of our capabilities and services, access to new markets and increased opportunities for growth.” 

Related Articles Read More >

AstraZeneca
AstraZeneca to invest $2B in Maryland, support 2,600 jobs
This is the logo of Novartis.
Novartis opens new manufacturing plant in California
samsung biologics (1)
Samsung Biologics completes Bioepis spinoff to become pure-play pharma CDMO
Eli Lilly the Netherlands Facility (1)
Lilly plans new oral medicine manufacturing plant in Europe
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE